Key result
The DaRe2THINK trial is a pragmatic, healthcare-embedded randomized trial designed to test whether earlier use of direct oral anticoagulants in patients with atrial fibrillation can prevent thromboembolic events and cognitive decline.
Why the study?
While electronic healthcare records enable large-scale trial screening and follow-up, robust and transparent methods are required to support high quality and clinically valuable research.
Does earlier use of direct oral anticoagulants prevent thromboembolic events and cognitive decline in patients with prior or current atrial fibrillation at low or intermediate risk of stroke?
Does earlier use of direct oral anticoagulants prevent thromboembolic events and cognitive decline in patients with prior or current atrial fibrillation at low or intermediate risk of stroke?
The DaRe2THINK trial methodology demonstrates a novel, systematic approach to conducting a pragmatic, 'no-visit' randomized controlled trial embedded within national electronic healthcare records.
Background Improving the efficiency of clinical trials is key to their continued importance in directing evidence-based patient care. Digital innovations, in particular the use of electronic healthcare records (EHR), allow for large-scale screening and follow-up of participants. However, it is critical these developments are accompanied by robust and transparent methods that can support high quality and high clinical value research. Methods The DaRe2THINK trial includes a series of novel processes, including nationwide pseudonymised pre-screening of the primary care EHR across England, digital enrolment, remote e-consent, and ‘no-visit’ follow-up by linking all primary and secondary care health data with patient-reported outcomes. Findings DaRe2THINK is a pragmatic, healthcare-embedded randomised trial testing whether earlier use of direct oral anticoagulants in patients with prior or current atrial fibrillation can prevent thromboembolic events and cognitive decline ( www.birmingham.ac.uk/dare2think ). This paper outlines the systematic approach and methodology employed to define patient information and outcome events. This includes transparency on all medical code lists and phenotypes used in the trial across a variety of national data sources, including Clinical Practice Research Datalink Aurum (primary care), Hospital Episode Statistics (secondary care) and the Office for National Statistics (mortality). Interpretation Co-designed by a patient and public involvement team, DaRe2THINK presents an opportunity to transform the approach to randomised trials in the setting of routine healthcare, providing high-quality evidence generation in populations representative of the community at-risk.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) studied Atrial fibrillation (n=3,000). Direct oral anticoagulant (DOAC) vs. Standard-of-care was evaluated on Thromboembolic events. The DaRe2THINK trial is a pragmatic, healthcare-embedded randomized trial designed to test whether earlier use of direct oral anticoagulants in patients with atrial fibrillation can prevent thromboembolic events and cognitive decline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: